Citi lowered the firm’s price target on Oric Pharmaceuticals to $14 from $15 and keeps a Buy rating on the shares post the Q1 report. The Q1 update was “incrementally informative” and most immediately in mid-2024 Oric is expecting to initiate clinical combination work for ORIC- 944, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
- ORIC Earnings this Week: How Will it Perform?
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Oric Pharmaceuticals participates in a conference call with JPMorgan
- ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC